Equity Overview
Price & Market Data
Price: $3.52
Daily Change: -$0.08 / 2.27%
Daily Range: $3.48 - $3.69
Market Cap: $1,660,662
Daily Volume: 26,162
Performance Metrics
1 Week: -3.56%
1 Month: -15.38%
3 Months: -45.43%
6 Months: -78.99%
1 Year: -95.00%
YTD: -83.61%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.